600267 Zhejiang Hisun Pharmaceutical
- 7.77
- -0.12-1.52%
Zhejiang Hisun Pharmaceutical News
Hisun Pharmaceutical Gets Nod to Market Eltrombopag; Shares Up 3%
Zhejiang Hisun Pharmaceutical (600267.SH): The active pharmaceutical ingredient of Apremilast obtains the Approval of Listing Application for Chemical Raw Materials.
On August 5th, Gelunhui reported that Zhejiang Hisun Pharmaceuticals Co., Ltd. (600267.SH) has received the "Chemical raw materials for Apixaban Ethanolamine" market approval application approval letter issued by the National Medical Products Administration on August 5, 2024. Apixaban Ethanolamine is indicated for use in adult and pediatric (6 years and older) chronic immune thrombocytopenia (ITP) patients who have responded poorly to glucocorticoids, immunoglobulins, and other therapies and who have increased risk of bleeding due to decreased platelet count. It increases platelet counts and reduces or prevents bleeding, and is only used for ITP patients at risk of bleeding caused by decreased platelet count and clinical conditions.
Is Zhejiang Hisun Pharmaceutical (SHSE:600267) A Risky Investment?
Hisun Pharmaceutical's Unit Gets Nod for Veterinary Drug
Hisun Pharmaceutical's Veterinary Arm Gets Registration Certificate for Mirtazapine Ointment
Zhejiang Hisun Pharmaceutical (600267.SH): The injection of Teicoplanin has passed the consistency evaluation of quality and efficacy of generic drugs.
On July 11th, Gelonhui reported that Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) received an approved and issued notification of supplementary drug application approval for injectable telavancin from the National Medical Products Administration. The company's injectable telavancin has passed the consistency evaluation of generic drug quality and efficacy. Injectable telavancin is used to treat various severe Gram-positive bacterial infections, including those that cannot be treated with penicillin or cephalosporin antibiotics; severe Staphylococcus aureus infections that cannot be treated with penicillin or cephalosporin antibiotics or have failed treatment with the above antibiotics; or Staphylococcus aureus infections resistant to other antibiotics. It has been proven effective.
Zhejiang Hisun Pharmaceutical (600267.SH): Its subsidiary received the "Approval Notice for Listing Application for Chemical Raw Materials" for its supply of active pharmaceutical ingredient of Efavirenz.
On July 10th, Gelunhui reported that Zhejiang Hisun Pharmaceutical(600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd. (referred to as "Hisun Hangzhou Company") received the "Chemical Raw Materials Application Approval Notice for Ivosidenib Raw Materials" issued and approved by the National Drug Administration. Ivosidenib is used for adult patients with advanced renal cell carcinoma who have failed previous treatment with sunitinib or sorafenib. It is also used for adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately or highly differentiated) progressing pancreatic neuroendocrine tumors and for those who cannot undergo surgical resection.
Hisun Pharmaceutical's Leukemia Drug Gets Marketing Approval
Zhejiang Hisun Pharmaceutical (600267.SH): The injection of acyclovir has obtained a drug registration certificate.
On June 26th, Gelunhui announced that its wholly-owned subsidiary, Hanhui Pharmaceuticals Co., Ltd., recently received the injection of Arabinofuranosyl Cytidine 《Pharmaceutical Registration Certificate》 issued by the National Medical Products Administration. Injection of Arabinofuranosyl Cytidine is mainly used for inducing and maintaining remission of acute non-lymphocytic leukemia in adults and children. The original manufacturer is Pfizer.
Zhejiang Hisun Pharmaceutical (600267.SH): Injection of levofloxacin hydrochloride passes generic drug consistency evaluation.
On June 26th, Gelonghui reported that Zhejiang Hisun Pharmaceutical (600267.SH) announced that its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd. (referred to as "Hanhui Pharmaceutical"), has received the injection of idarubicin hydrochloride approved supplement application approval notice issued by the State Drug Administration. Hanhui Pharmaceutical's drug injection of idarubicin hydrochloride has passed the consistency evaluation of generic drug quality and efficacy. Injection of idarubicin hydrochloride is suitable for adult induction remission of acute non-lymphocytic leukemia (ANLL) without previous treatment and induction remission of adult relapsed and refractory ANLL, as well as acute lymphoblastic leukemia for adults and children.
Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Stock Price Dropped 4.8% Last Week; Individual Investors Would Not Be Happy
Hisun Pharmaceutical Unit's Cladribine Injection Passes Regulatory Evaluation
Zhejiang Hisun Pharmaceutical (600267.SH): KeLaqubin Injection passed the consistency evaluation of generic drugs.
On June 18, Gelunhui reported that its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., received the Approval Notice of Supplemental Application for Drug Approval from the National Medical Products Administration for the injection of Cladribine, and Hanhui's Cladribine injection, a pharmaceutical product, has passed the consistency evaluation of quality and efficacy of generic drugs. Cladribine injection is used to treat hairy cell leukemia (HCL) with active clinical significance of anemia, neutropenia, thrombocytopenia, and disease-related symptoms after interferon treatment failure.
Zhejiang Hisun Pharmaceutical's subsidiary has been granted a government subsidy of 13 million yuan.
Zhejiang Hisun Pharmaceutical (600267.SH) announced that its subsidiary, Hui Zheng (Shanghai) Pharmaceutical Technology Co., Ltd., recently received a government subsidy of 13 million yuan related to revenue, accounting for 13.95% of the company's audited net income for the latest period.
Hisun Pharmaceutical's Veterinary Arm Gets Nod to Produce Fenbendazole Oral Suspension
Why Investors Shouldn't Be Surprised By Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Low P/S
Hisun Pharma's Veterinary Arm Gets Approval to Register Amoxicillin and Clavulanate Potassium Dry Suspension
Hisun Pharma's Veterinary Arm Gets Nod to Market Selamectin Drops
Haizheng Pharmaceutical (600267.SH): In terms of synthetic biology, results have been achieved in improving the production level of core strains through gene editing technology
Gelonghui, May 10, 丨 Haizheng Pharmaceutical (600267.SH) said on the interactive platform that in terms of synthetic biology, the company achieved results in improving the production level of core strains through gene editing technology; at the same time, it uses yeast, Escherichia coli, Corynebacterium glutamate, etc. to lay out raw materials such as new materials, functional foods, and functional skincare products; the enzyme catalytic technology platform has approved a raw material with a full enzymatic process, and is also developing multiple pharmacological intermediate processes, focusing on targeted screening of transaminases, redoxases, transferases, and ligases.
Haizheng Pharmaceutical (600267.SH): Existing varieties of orlistat in the field of diet pills
Gelonghui, May 10 | Haizheng Pharmaceutical (600267.SH) said on an interactive platform that the company currently has a variety of orlistat in the field of diet pills.
Analysis
Price Target
No Data
